Andrew K. Godwin

Andrew K. Godwin, Ph.D., is a Chancellor’s Distinguished Chair in Biomedical Sciences Endowed Professor, Division Director of Genomic Diagnostics, and Director of Molecular Oncology at the University of Kansas Medical Center (KUMC). He is Deputy Director of the NCI-Designated KU Comprehensive Cancer Center and Founding Director of the Kansas Institute for Precision Medicine, the Biospecimen Shared Resource, and the Center for Genomic Services and Health Equity. With over 550 peer-reviewed publications and an h-index of 144, his work bridges basic and clinical sciences to advance precision oncology.

• Chancellor’s Distinguished Chair in Biomedical Sciences
• Division Director, Genomic Diagnostics
• Deputy Director, KU Cancer Center
• Founding Director, Kansas Institute for Precision Medicine
• Director, Biospecimen Shared Resource
• Director, Center for Genomic Services and Health Equity

Dr. Godwin's research focuses on early cancer detection, liquid biopsies, and molecular therapeutics. His laboratory investigates extracellular vesicle biology, biosample ascertainment, and companion diagnostics to improve patient outcomes in ovarian cancer, breast cancer, and Ewing sarcoma. Recent work emphasizes multi-omics approaches for biomarker validation and therapeutic development.

His laboratory has produced groundbreaking studies on AKT2 activation in ovarian cancer, KRAS mutations in EGFR-targeted therapy, and circulating tumor cell diagnostics. Current research trends integrate spatial transcriptomics, mitochondrial DNA mutations, and immune microenvironment profiling across cancer types.

Scientific honors include:

• Dolph C. Simons, Sr. Higuchi Award (2020)
• KU Mentoring Awards (2021, 2024)
• NIH/NIGMS COBRE Grant ($24M total)
• CELLSEARCH® Clinical Validation Leadership

Dr. Godwin mentors over 150 trainees across career stages and leads KUMC's Clinical Molecular Oncology Laboratory (CMOL) and Biomarker Discovery Lab (BDL), advancing team science and translational research infrastructure.